Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination immunosuppressive therapy consisting of a glucocorticoid and tacrolimus, primarily used to prevent organ rejection in transplant recipients. Tacrolimus is a calcineurin inhibitor that inhibits T-cell activation by preventing the dephosphorylation reactions required for lymphokine gene transcription. Glucocorticoids provide complementary immunosuppressive effects through different mechanisms. This combination is often used with other immunosuppressants like mycophenolate mofetil in transplant protocols.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucocorticoid + tacrolimus.